Join to View Full Profile
7910 W Jefferson BlvdSte 108Fort Wayne, IN 46804
Phone+1 260-484-8830
Fax+1 260-483-1911
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Sunil Babu, MD is an oncologist in Fort Wayne, Indiana. He is currently licensed to practice medicine in Indiana, Ohio, and New York.
Education & Training
Westchester Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008- Westchester Medical CenterResidency, Internal Medicine, 2000 - 2003
St. John's Medical CollegeClass of 2000
Certifications & Licensure
IN State Medical License 2008 - 2025
OH State Medical License 2021 - 2025
NY State Medical License 2003 - 2006
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 2 citationsPhase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03.Afshin Dowlati, Anne C Chiang, Andrés Cervantes, Sunil Babu, Erika Hamilton
Journal of Thoracic Oncology. 2025-01-02 - 22 citationsGenetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine.Hartmut Döhner, Keith W Pratz, Courtney D DiNardo, Andrew H Wei, Brian A Jonas
Blood. 2024-11-21 - 67 citationsOutcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine.Daniel A Pollyea, Keith W Pratz, Andrew H Wei, Vinod Pullarkat, Brian A Jonas
Clinical Cancer Research. 2022-12-15
Press Mentions
Don’t Leave Money on the Table: Oncology Practice Leaders Discuss Payer Contract ConcernsMay 4th, 2025- Clinical Trials in Community Oncology: Demand High for More Studies and PatientsApril 30th, 2025
The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid TumorsMarch 9th, 2021
